Focused On-demand Library for Coiled-coil domain-containing protein 34

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96HJ3

UPID:

CCD34_HUMAN

Alternative names:

Renal carcinoma antigen NY-REN-41

Alternative UPACC:

Q96HJ3; B2R8G2; Q8IX69; Q9H2A6; Q9Y599

Background:

Coiled-coil domain-containing protein 34, also known as Renal carcinoma antigen NY-REN-41, plays a crucial role in spermatogenesis. It is specifically involved in anterograde intraflagellar transport, a process vital for the formation of sperm flagella. This protein's function underscores its importance in the reproductive system, particularly in the development of spermatozoa.

Therapeutic significance:

Spermatogenic failure 76, a male infertility disorder characterized by oligoasthenoteratozoospermia and abnormally shaped spermatozoa, is associated with mutations affecting this protein. Understanding the role of Coiled-coil domain-containing protein 34 could open doors to potential therapeutic strategies for treating this infertility disorder.